Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost-saving <I>versus</I> a higher maintenance dose of B/F or salmeterol/fluticasone (S/F)

Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost-saving versus a higher maintenance dose of B/F or salmeterol/fluticasone (S/F)

D. Price, A. Wiren, P. Kuna (Aberdeen, United Kingdom; Lund, Sweden; Lodz, Poland)

Source: Annual Congress 2006 - Recent advances in treatment of COPD

Session: Recent advances in treatment of COPD
Session type: Thematic Poster Session
Number: 1274

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Price, A. Wiren, P. Kuna (Aberdeen, United Kingdom; Lund, Sweden; Lodz, Poland). Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost-saving versus a higher maintenance dose of B/F or salmeterol/fluticasone (S/F). Eur Respir J 2006; 28: Suppl. 50, 1274

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Budesonide/formoterol adjustable maintenance dosing (B/F AMD) reduces the burden of asthma more effectively than fixed-dosing (FD) with B/F or salmeterol/fluticasone (S/FL) Source: Eur Respir J 2004; 24: Suppl. 48, 508s Year: 2004
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Adjustable maintenance dosing (AMD) with budesonide/formoterol (B/F) meets guideline-defined management goals more effectively than fixed dosing (FD) with B/F or salmeterol/fluticasone (S/FL) Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007
Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009
Quality of life of stable dose treatment with salmeterol/fluticasone (SFC) compared with adjustable maintenance dosing (AMD) with formoterol/budesonide (FBC) Source: Eur Respir J 2005; 26: Suppl. 49, 252s Year: 2005
EXCEL: regular maintenance therapy with salmeterol/fluticasone propionate combination (SFC) reduces exacerbations more effectively than with formoterol/budesonide combination (FBC) Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Budesonide/formoterol maintenance and reliever therapy – effective treatment at a lower cost Source: Annual Congress 2008 - Rationale of self-education in asthma therapy Year: 2008
Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Source: Eur Respir J 2005; 26: 819-828 Year: 2005
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β₂agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003